MOONLAKE IMMUNOTHERAPEUTICS Ttl Fee Amt
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) had Ttl Fee Amt of $41.43 thousand as of 2026-08-10, per its S-3ASR filed 2026-08-10.
Financial Statements › Notes
ffd:TtlFeeAmt · last filed 2026-08-10
- 2026-08-10: Ttl Fee Amt $41.43K.
- 2026-08-04: Ttl Fee Amt $12.17K.
| Period end | Ttl Fee Amt |
|---|---|
| 2026-08-10 | $41.43K S-3ASR · filed 2026-08-10 |
| 2026-08-04 | $12.17K S-8 · filed 2026-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |